Agilent Technologies (NYSE:A) Price Target Cut to $157.00 by Analysts at TD Cowen

Agilent Technologies (NYSE:A) had its price objective reduced by TD Cowen from $170.00 to $157.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other research firms also recently issued reports on A. UBS Group boosted their price objective on shares of Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Morgan Stanley began coverage on shares of Agilent Technologies in a research report on Tuesday, December 2nd. They issued an “overweight” rating on the stock. The Goldman Sachs Group initiated coverage on shares of Agilent Technologies in a research note on Tuesday, December 9th. They issued a “buy” rating and a $170.00 price objective on the stock. Robert W. Baird lifted their price objective on Agilent Technologies from $142.00 to $165.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 25th. Finally, Citigroup raised their price objective on Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Agilent Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $161.29.

Agilent Technologies Stock Performance

Shares of A opened at $121.00 on Thursday. The firm has a fifty day simple moving average of $134.99 and a 200 day simple moving average of $135.87. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $160.27. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $34.22 billion, a price-to-earnings ratio of 26.71, a PEG ratio of 3.62 and a beta of 1.30.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The firm had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.95%. The business’s revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Research analysts forecast that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be given a $0.255 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.8%. Agilent Technologies’s payout ratio is 22.32%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of A. Norges Bank bought a new stake in shares of Agilent Technologies in the fourth quarter worth about $549,158,000. Massachusetts Financial Services Co. MA boosted its holdings in Agilent Technologies by 13.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock worth $1,925,064,000 after purchasing an additional 1,713,216 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Agilent Technologies by 424.1% during the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after purchasing an additional 1,652,244 shares during the period. Ameriprise Financial Inc. grew its position in shares of Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after acquiring an additional 1,340,161 shares during the period. Finally, Troy Asset Management Ltd increased its holdings in Agilent Technologies by 74.3% in the 2nd quarter. Troy Asset Management Ltd now owns 2,397,820 shares of the medical research company’s stock worth $282,967,000 after acquiring an additional 1,021,865 shares in the last quarter.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Management set a FY‑26 revenue target of $7.3B–$7.5B and said it is expanding its “Ignite” operating system to drive margin improvement — a strategic signal that management expects revenue and margin expansion over the year. Agilent outlines $7.3B–$7.5B FY26 revenue target
• Positive Sentiment: Company-issued guidance: FY‑26 EPS range of 5.900–6.040 and Q2 EPS guidance roughly in-line with consensus, which provides a forward box for expectations and suggests management confidence despite a soft quarter. Agilent earnings/guidance details
• Neutral Sentiment: Top line growth remains positive — revenue rose about 7% YoY to ~$1.80B — but it narrowly missed some sell‑side estimates, leaving the print mixed from a growth standpoint. Agilent Q1 earnings/revenue recap
• Negative Sentiment: EPS missed consensus by $0.01 (reported $1.36 vs. ~$1.37 consensus) and revenue came in slightly below estimates; management cited a U.S. winter snowstorm that disrupted shipments and hurt margins — the immediate driver of the share decline. Agilent shares fall after Q1 earnings miss
• Negative Sentiment: Profitability and cash-flow signs were weak: operating profit and operating cash flow declined year-over-year, which raises near-term margin and free-cash-flow concerns for investors focused on quality of earnings. Q1 results: cash flow and profit weakness
• Negative Sentiment: Several brokers trimmed price targets (UBS, TD Cowen, Wells Fargo, Barclays) while largely maintaining buy/overweight ratings — a sign of reduced near‑term upside and caution among analysts despite longer‑term positive views. Analyst price target changes

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.